QURE
uniQure N.V. NASDAQ Listed Feb 5, 2014$24.18
After hrs
$28.28
+2.26%
Mkt Cap $1.5B
52w Low $8.73
24.6% of range
52w High $71.50
50d MA $16.64
200d MA $25.56
P/E (TTM)
-5.5x
EV/EBITDA
-10.3x
P/B
5.5x
Debt/Equity
2.7x
ROE
-100.0%
P/FCF
-7.7x
RSI (14)
—
ATR (14)
—
Beta
0.75
50d MA
$16.64
200d MA
$25.56
Avg Volume
3.2M
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Paasheuvelweg 25a · Amsterdam 1105 BP · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | BMO | -0.93 | -0.56 | +39.8% | 10.50 | -12.7% | -14.0% | -14.0% | -13.9% | +1.4% | +35.9% | — |
| Nov 10, 2025 | BMO | -0.85 | -1.38 | -62.4% | 26.15 | +1.3% | +17.9% | +17.9% | +15.2% | +16.0% | +14.3% | — |
| Jul 29, 2025 | BMO | -0.89 | -0.69 | +22.5% | 13.68 | +8.6% | +5.7% | +5.7% | +1.8% | +0.1% | +0.7% | — |
| May 9, 2025 | BMO | -1.07 | -0.82 | +23.4% | 12.79 | -0.2% | +2.8% | +2.8% | +0.2% | -1.1% | +3.6% | — |
| Feb 27, 2025 | BMO | -0.60 | -1.50 | -150.0% | 12.07 | -5.1% | +8.9% | +8.9% | -9.7% | -6.1% | +0.2% | — |
| Nov 5, 2024 | BMO | -1.12 | -0.91 | +18.8% | 6.06 | +1.5% | +18.2% | +18.2% | +22.6% | +28.5% | +26.4% | — |
| Aug 1, 2024 | BMO | -1.24 | -1.16 | +6.5% | 7.48 | -0.7% | -2.3% | -2.3% | +1.3% | +1.1% | -4.8% | — |
| May 7, 2024 | BMO | -1.31 | -1.36 | -3.8% | 4.82 | -1.5% | +1.5% | +1.5% | +5.2% | +2.1% | +1.2% | — |
| Feb 28, 2024 | BMO | -1.54 | -1.53 | +0.6% | 6.69 | -8.5% | -14.1% | -14.1% | -16.4% | -22.9% | -24.7% | — |
| Nov 7, 2023 | BMO | -1.49 | -1.88 | -26.2% | 6.88 | +3.1% | -5.4% | -5.4% | -9.2% | -12.0% | -12.9% | — |
| Aug 1, 2023 | BMO | 2.97 | -1.44 | -148.5% | 10.62 | -2.3% | -5.3% | -5.3% | -9.0% | -11.3% | -16.0% | — |
| May 9, 2023 | BMO | -1.02 | -1.63 | -59.8% | 21.79 | +0.9% | +1.9% | +1.9% | +1.7% | +0.4% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Goldman Sachs | Maintains | Neutral → Neutral | — | $17.58 | $17.50 | -0.5% | +2.6% | -0.7% | +1.1% | -0.2% | +2.6% |
| Mar 23 | Barclays | Maintains | Equal Weight → Equal Weight | — | $16.09 | $16.06 | -0.2% | -1.1% | -5.7% | +1.7% | -3.0% | -8.2% |
| Mar 11 | Mizuho | Upgrade | Neutral → Outperform | — | $18.26 | $18.51 | +1.4% | -3.8% | -7.2% | -15.0% | -12.7% | -14.5% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.99 | $17.96 | -0.2% | +1.5% | -2.4% | -5.8% | -13.7% | -11.4% |
| Mar 9 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $14.27 | $18.02 | +26.3% | +26.1% | +28.0% | +23.1% | +18.7% | +8.8% |
| Mar 9 | Chardan Capital | Maintains | Buy → Buy | — | $14.27 | $18.02 | +26.3% | +26.1% | +28.0% | +23.1% | +18.7% | +8.8% |
| Mar 9 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $14.27 | $18.02 | +26.3% | +26.1% | +28.0% | +23.1% | +18.7% | +8.8% |
| Mar 3 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $10.50 | $9.17 | -12.7% | -14.0% | -13.9% | +1.4% | +35.9% | +71.3% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $10.50 | $9.17 | -12.7% | -14.0% | -13.9% | +1.4% | +35.9% | +71.3% |
| Mar 3 | Mizuho | Downgrade | Outperform → Neutral | — | $10.50 | $9.17 | -12.7% | -14.0% | -13.9% | +1.4% | +35.9% | +71.3% |
| Mar 3 | Chardan Capital | Maintains | Buy → Buy | — | $10.50 | $9.17 | -12.7% | -14.0% | -13.9% | +1.4% | +35.9% | +71.3% |
| Mar 2 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $15.63 | $9.19 | -41.2% | -32.8% | -42.2% | -42.2% | -31.9% | -8.7% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.05 | $25.55 | -1.9% | -5.1% | -7.4% | -14.1% | -21.3% | -16.5% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $20.14 | $20.00 | -0.7% | -1.9% | -3.1% | +1.4% | +8.7% | +14.3% |
| Dec 9 | Mizuho | Maintains | Outperform → Outperform | — | $21.77 | $21.62 | -0.7% | -4.5% | -7.5% | -9.3% | -10.4% | -6.2% |
| Dec 4 | Chardan Capital | Maintains | Buy → Buy | — | $25.48 | $21.25 | -16.6% | -10.8% | -16.3% | -14.6% | -18.4% | -21.0% |
| Nov 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $30.84 | $29.86 | -3.2% | -2.3% | -1.6% | -3.1% | -1.7% | -3.7% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $26.15 | $26.49 | +1.3% | +17.9% | +15.2% | +16.0% | +14.3% | +16.0% |
| Nov 10 | Leerink Partners | Maintains | Outperform → Outperform | — | $27.79 | $26.50 | -4.6% | -5.9% | +11.0% | +8.4% | +9.2% | +7.5% |
| Nov 4 | William Blair | Downgrade | Outperform → Market Perform | — | $34.29 | $30.81 | -10.1% | -11.2% | -24.0% | -19.8% | -19.0% | -23.7% |
| Nov 4 | Goldman Sachs | Maintains | Neutral → Neutral | — | $34.29 | $30.81 | -10.1% | -11.2% | -24.0% | -19.8% | -19.0% | -23.7% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.29 | $30.81 | -10.1% | -11.2% | -24.0% | -19.8% | -19.0% | -23.7% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $34.29 | $30.81 | -10.1% | -11.2% | -24.0% | -19.8% | -19.0% | -23.7% |
| Nov 3 | Chardan Capital | Maintains | Buy → Buy | — | $67.69 | $23.05 | -65.9% | -49.3% | -55.0% | -61.5% | -59.4% | -58.9% |
| Oct 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.92 | $55.55 | +1.1% | -3.7% | +5.5% | +9.2% | +15.9% | +12.1% |
| Oct 2 | Wells Fargo | Maintains | Overweight → Overweight | — | $54.99 | $55.87 | +1.6% | -0.9% | -0.1% | -3.8% | +5.3% | +9.1% |
| Sep 25 | Chardan Capital | Maintains | Buy → Buy | — | $47.50 | $50.43 | +6.2% | +10.8% | +14.3% | +25.1% | +22.9% | +15.8% |
| Sep 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $47.50 | $50.43 | +6.2% | +10.8% | +14.3% | +25.1% | +22.9% | +15.8% |
| Sep 25 | Mizuho | Maintains | Outperform → Outperform | — | $47.50 | $50.43 | +6.2% | +10.8% | +14.3% | +25.1% | +22.9% | +15.8% |
| Sep 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $47.50 | $50.43 | +6.2% | +10.8% | +14.3% | +25.1% | +22.9% | +15.8% |
| Sep 25 | Guggenheim | Maintains | Buy → Buy | — | $47.50 | $50.43 | +6.2% | +10.8% | +14.3% | +25.1% | +22.9% | +15.8% |
| Sep 25 | Goldman Sachs | Maintains | Neutral → Neutral | — | $47.50 | $50.43 | +6.2% | +10.8% | +14.3% | +25.1% | +22.9% | +15.8% |
| Sep 24 | Leerink Partners | Maintains | Outperform → Outperform | — | $13.66 | $39.36 | +188.1% | +247.7% | +285.4% | +297.6% | +334.8% | +327.3% |
| Sep 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.66 | $39.36 | +188.1% | +247.7% | +285.4% | +297.6% | +334.8% | +327.3% |
| Sep 24 | Stifel | Maintains | Buy → Buy | — | $13.66 | $39.36 | +188.1% | +247.7% | +285.4% | +297.6% | +334.8% | +327.3% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.95 | $18.16 | +1.2% | -2.9% | -2.6% | -2.6% | -5.6% | -8.1% |
| Sep 8 | Chardan Capital | Maintains | Buy → Buy | — | $17.95 | $18.16 | +1.2% | -2.9% | -2.6% | -2.6% | -5.6% | -8.1% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.73 | $17.92 | +1.1% | +1.2% | -1.7% | -1.4% | -1.4% | -4.5% |
| Aug 29 | Chardan Capital | Maintains | Buy → Buy | — | $16.26 | $16.27 | +0.1% | +0.4% | +4.6% | +6.9% | +9.0% | +10.4% |
| Jul 29 | Chardan Capital | Maintains | Buy → Buy | — | $14.98 | $14.74 | -1.6% | -8.7% | -3.5% | -7.1% | -8.5% | -8.1% |
| May 30 | Chardan Capital | Maintains | Buy → Buy | — | $14.90 | $14.77 | -0.9% | -2.9% | -2.8% | +1.7% | +0.4% | +11.5% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.04 | $15.90 | +5.7% | -0.9% | -3.8% | -3.7% | +0.8% | -0.5% |
| May 12 | Chardan Capital | Maintains | Buy → Buy | — | $12.79 | $12.76 | -0.2% | +2.8% | +0.2% | -1.1% | +3.6% | +7.1% |
| May 12 | Guggenheim | Maintains | Buy → Buy | — | $12.79 | $12.76 | -0.2% | +2.8% | +0.2% | -1.1% | +3.6% | +7.1% |
| May 6 | Chardan Capital | Maintains | Buy → Buy | — | $15.89 | $15.51 | -2.4% | -27.8% | -36.7% | -22.9% | -19.5% | -17.2% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.00 | $12.94 | -0.5% | +2.2% | +10.7% | +10.7% | +9.7% | +9.1% |
| Apr 1 | Chardan Capital | Maintains | Buy → Buy | — | $10.60 | $10.77 | +1.6% | -6.5% | +0.2% | -8.0% | -15.5% | -17.4% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.90 | $10.71 | -1.7% | +3.9% | +10.9% | +14.8% | +12.2% | +7.3% |
| Feb 28 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $12.07 | $11.46 | -5.1% | +8.9% | -9.7% | -6.1% | +0.2% | +3.6% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.67 | $15.89 | +1.4% | +0.8% | -2.2% | -2.7% | +0.8% | +0.4% |
No insider trades available.
8-K · 2.02
!! High
uniQure N.V. -- 8-K 2.02: Earnings Results
uniQure reported financial results via press release, with detailed operational and financial condition updates available in the attached exhibit for investor review.
May 5
8-K · 7.01
! Medium
uniQure N.V. -- 8-K 7.01: Regulation FD Disclosure
uniQure (QURE) disclosed material information via press release to comply with Regulation FD, ensuring equal public access to company announcements without prior selective disclosure to investors.
Apr 30
8-K · 7.01
! Medium
uniQure N.V. -- 8-K 7.01: Regulation FD Disclosure
uniQure announced a regulatory update on AMT-130, its investigational Huntington's disease gene therapy, potentially signaling progress toward commercialization or addressing previous regulatory concerns.
Mar 2
Data updated apr 26, 2026 9:44pm
· Source: massive.com